

Silva Pharmaceuticals Limited


Un-Audited Financial Statements (Third Quarter)

For the Period from 01 July, 2020 to 31 March, 2021


SILVA PHARMACEUTICALS LTD.
Statement of Financial Position (Un-Audited)
As at 31 March, 2021

Particulars	Notes	Amount in Taka	
		31-Mar-21	30-Jun-20
ASSETS			
Non Current Assets		1,378,269,835	1,365,926,835
Property, Plant & Equipment	3.00	1,189,512,437	1,221,249,900
Intangible Assets	4.00	1,725,901	1,178,827
Right-of-use asset (ROU)	5.00	17,590,885	21,712,480
Capital work-in-Progress	6.00	169,440,612	121,785,628
Current Assets		1,178,079,832	1,090,279,961
Inventories	7.00	459,107,282	444,378,778
Trade and Other Receivables	8.00	272,898,285	263,426,843
Advances, Deposits and Prepayments	9.00	174,753,565	143,026,882
Fixed Deposits Receipts (FDR)		211,125,258	203,035,178
Cash and Cash Equivalents	10.00	60,195,442	36,412,280
Total Assets		2,556,349,667	2,456,206,796
SHAREHOLDERS EQUITY AND LIABILITIES:			
Equity attributable to the Shareholders		2,250,165,750	2,198,109,877
Share Capital	11.00	1,365,000,000	1,365,000,000
Retained Earnings	12.00	885,165,750	833,109,877
Non-Current Liabilities		97,140,460	98,260,873
Deferred Tax Liabilities	13.00	87,826,904	84,977,387
Lease liabilities	14.00	9,313,556	13,283,486
Current Liabilities		209,043,457	159,836,046
Lease liabilities	14.00	5,570,729	5,722,394
Trade and Other Payables	15.00	6,564,640	6,542,477
Unclaimed Dividend Account		1,587,504	1,327,360
Short Term Loan		46,989,411	26,680,475
Provision for Expenses	16.00	148,331,173	119,563,340
Total Liabilities		306,183,917	258,096,919
Total Equity & Liabilities:		2,556,349,667	2,456,206,796
Net Assets Value (NAV) per share	22.00	16.48	16.10

The annexed notes from an integral part of these financial statements.



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary


Place: Dhaka;


Dated: April 28, 2021


Silva Pharmaceuticals Ltd
Statements of Profit or Loss and Other Comprehensive Income (Un-Audited)
For the Third Quarter ended 31 March, 2021


Particulars	Notes	Amount in Taka			
		Third Quarter ended Results		Quarterly Results	
		01/07/2020 to 31/03/2021	01/07/2019 to 31/03/2020	01/01/2021 to 31/03/2021	01/01/2020 to 31/03/2020
Turnover		609,867,696	593,440,754	191,439,818	187,854,852
Cost of goods sold	17.00	(355,097,562)	(348,821,502)	(111,355,344)	(109,440,762)
Gross Profit		254,770,134	244,619,252	80,084,474	78,414,090
Operating expenses	18.00	(124,369,895)	(119,486,662)	(46,979,651)	(46,564,783)
Operating Income		130,400,239	125,132,590	33,104,823	31,849,307
Financial expenses		(1,945,384)	-	(593,818)	-
Net Operating Profit		128,454,855	125,132,590	32,511,005	31,849,307
Interest and Other income		10,498,877	17,950,960	2,920,451	5,563,400
Net Profit before Contribution to WPPF		138,953,732	143,083,550	35,431,456	37,412,707
Worker's Profit Participation Fund (WPPF)	19.00	(6,616,844)	(6,813,502)	(1,687,212)	(1,781,557)
Net Profit before Income Tax		132,336,888	136,270,048	33,744,244	35,631,150
Income Tax Expenses:	20.00	(32,789,515)	(34,067,512)	(8,326,836)	(8,907,788)
Current Tax Expenses	20.01	(29,939,998)	(29,549,761)	(7,127,895)	(7,238,766)
Deferred Tax (expenses)/ Income	20.02	(2,849,517)	(4,517,751)	(1,198,941)	(1,669,022)
Net Profit after tax		99,547,373	102,202,536	25,417,408	26,723,362
Earnings Per Share (EPS)	21.00	0.73	0.75	0.19	0.20

The annexed notes from an integral part of these financial statements.


 Chairman


 Managing Director


 Director


 Chief Financial Officer


 Company Secretary


Place: Dhaka;
 Dated: April 28, 2021

SILVA PHARMACEUTICALS LTD.
Statement of Changes in Equity (Un-Audited)
For the Third Quarter ended 31 March, 2021


Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2020	1,365,000,000	833,109,877	2,198,109,877
Net profit after tax during the period	-	99,547,373	99,547,373
Dividend Paid in Cash	-	(47,491,500)	(47,491,500)
Balance as at 31 March, 2021	1,365,000,000	885,165,750	2,250,165,750

For the Third Quarter ended 31 March, 2020


Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2019	1,300,000,000	833,442,946	2,133,442,946
Net profit after tax during the period	-	102,202,536	102,202,536
Issue of Share Capital through Stock Dividend	65,000,000	(65,000,000)	-
Dividend Paid in Cash	-	(54,276,000)	(54,276,000)
Balance as at 31 March, 2020	1,365,000,000	816,369,482	2,181,369,482




 Chairman



 Managing Director



 Director



 Chief Financial Officer




 Company Secretary


Place: Dhaka;
 Dated: April 28, 2021


SILVA PHARMACEUTICALS LTD.
Statement of Cash Flows (Un-Audited)
For the Third Quarter ended 31 March, 2021


Particulars	Amount in Taka	
	01/07/2020 to 31/03/2021	01/07/2019 to 31/03/2020
Cash flows from Operating Activities		
Cash received from Customers	599,580,411	589,086,907
Cash received from non-operating income	11,314,720	16,138,511
Cash Paid to Suppliers	(332,338,364)	(312,067,916)
Cash Paid to Employees	(106,778,505)	(100,642,413)
Cash Paid for Others	(15,559,712)	(25,141,476)
Income Tax Paid	(25,777,999)	(24,727,907)
Net cash inflows/(outflows) from operating activities (A)	130,440,551	142,645,706
Cash flows from Investing Activities		
Acquisition of Property, Plant and Equipment	(8,299,636)	(42,169,419)
Cash Payments for Capital Work-in-progress	(57,018,130)	(68,202,026)
Cash received/Payments from/to FDR	(8,090,080)	35,800,000
Net cash inflows/(outflows) used in investing activities (B)	(73,407,846)	(74,571,445)
Cash flows from Financing Activities		
Short Term Loan received/(Repaid)	20,308,936	-
Cash payment for Financial Expenses	(1,197,620)	-
Cash payment towards lease liabilities	(4,869,359)	-
Cash Dividend Paid	(47,491,500)	(54,276,000)
Net cash inflows/(outflows) provided financing activities (C)	(33,249,543)	(54,276,000)
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)	23,783,162	13,798,261
Cash and Cash Equivalents at the beginning of the period	36,412,280	42,391,451
Cash and Cash Equivalents at the end of the period	60,195,442	56,189,712
Net Operating Cash Flow Per Share	0.96	1.05

Note- 23


 Chairman


 Managing Director


 Director


 Chief Financial Officer


 Company Secretary

Place: Dhaka;
 Dated: April 28, 2021